KJX839
Showing 1 - 11 of 11
Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)
Not yet recruiting
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Inclisiran
- Matching Placebo for Inclisiran
- (no location specified)
May 24, 2023
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Heterozygous or Homozygous Familial Hypercholesterolemia Trial (Inclisiran)
Not yet recruiting
- Heterozygous or Homozygous Familial Hypercholesterolemia
- (no location specified)
Dec 27, 2022
Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg
Completed
- Hyperlipidemia
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
- +2 more
-
Changsha, Hunan, China
- +2 more
Dec 2, 2021
Hypercholesterolemia Trial in Worldwide (inclisiran sodium, Placebo)
Active, not recruiting
- Hypercholesterolemia
- inclisiran sodium
- Placebo
-
Lanzhou, Gansu, China
- +44 more
Feb 7, 2022
Familial Hypercholesterolemia - Heterozygous Trial in Worldwide (Inclisiran, Placebo)
Recruiting
- Familial Hypercholesterolemia - Heterozygous
- Inclisiran
- Placebo
-
Tucson, Arizona
- +76 more
Aug 8, 2022
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Coronary Artery Disease Trial in Worldwide (Inclisiran sodium 300 mg, Placebo)
Recruiting
- Coronary Artery Disease
- Inclisiran sodium 300 mg
- Placebo
-
Huntsville, Alabama
- +54 more
Jan 31, 2023
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Inclisiran
- Behavioural Support
-
Sale, Cheshire, United Kingdom
- +16 more
Jan 20, 2023